[1] Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology’s practise parameters. Neurology 1997;49:925
- Corey-Bloom J, Thal LJ, Galasko D, Folstein M, Drachman D, Raskind M, Lanska DJ.Diagnosis and evaluation of dementia. Neurology 1995;45:211-218
- Scheltens P. Early diagnosis of dementia: neuroimaging. Journal of Neurology 1999;246:16

[2] Jack, C.R., Petersen, C.R., et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Annals of Neurology 1998; 43:303
- Mosconi L, Perani D, Sorbi S et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology (in press)
- Zakzanis KK. Quantitative evidence for neuoroanatomic and neuropsychological markers in dementia of the Alzheimer’s type. Journal of Clinical Experimental Neuropsychology 1998;20:259.

[3] Pullicino P, Benedict RHB, et al. Neuroimaging criteria for vascular dementia. Archives of Neurology 1996;723

[4] Ylikoski A, Erkinjuntti T, et al. White matter hyperintensities on MRI in the neurologically non-diseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 1995;26:1171109,110).

[5] Bhatia S, Bookheimer SY, et al. Measurement of whole temporal lobe and hippocampus for MR volumetry: normative data. Neurology 1993;43:2006

[6] de Leon MJ, Convit A, Desanti S, et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer’s disease. Int Psychogeriatr 1997;9:183

[7] Jobst KA, Smith AD, et al. Detection in life of confirmed Alzheimer’s disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340:1179

[8] Eslinger P, Damasio H, et al.Examining the relationship between computed tomography and neuropsychological measures in normal and demented elderly. Journal of Neurology Neurosurgery and Psychiatry 1984;47:1319

[9] Frisoni GB, et al. The added value of neuroimaging for diagnosing dementia.American Journal of Neuroradiology 1999;47:1999
- Scheltens P, Leys D, et al. Atrophy of medial temporal lobes on MRI in «probable» Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. Journal of Neurology Neurosurgery and Psychiatry 1992;55:967

[10] Soininen HS, Scheltens P. Early diagnostic indices for the prevention of Alzhaimer’s disease. Ann Med 1998;30:553-559

[11] Killiany RJ, Moss MB, et al. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Archives of Neurology 1993;50:949

[12] Frackowiak RSJ, Friston KJ, et al. Human Brain Mapping. San Diego, Academic Press, 1997

[13] Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001; 57:1756-63

[14] Chetelat G, Baron JC Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage. 2003 Feb;18(2):525-41

[16] Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992; 115:1783-1806
- Neary D, Snowden JS, Mann DM. The clinical pathological correlates of lobar atrophy. Dementia 1993; 4:154-9
- Edwards-Lee T, Miller BL, Benson DF, Cummings J, Russel EL, Boone K et al. The temporal variant of frontotemporal dementia. Brain 1997; 120: 1027-40

[17] Caselli RJ, Jack CR. Asymmetric cortical degeneration syndromes. A proposed classification, Archives of Neurology 1992;49:770

[18] Mummery C, Patterson K, Price C, Ashburner J, Frackowiak RSJ, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000; 47: 36-45

[19] Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ Shuff N, Weiner M et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198-208
- Boxer AL, Rankin KP, Miller BL, Schuff N, Weiner M, Gorno-Tempini ML, Rosen. Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia. Arch Neurol. 2003 Jul;60(7):949-56
- Kitagaki H, Mori E, et al. Frontotemporal dementia and Alzheimer’s disease: evaluation of cortical atrophy with automated hemisheric surface display generated with MR images. Radiology 1998;208:431

[20] Frackowiak RSJ, Friston KJ, et al. Human Brain Mapping. San Diego, Academic Press, 1997
- Signorini M, Paulesu E, Friston K, Perani D, Lucignani G, Colleluori A, Striano G, et al. Rapid assessment of [18F]FDGPET brain scans in individual patients with Statistical Parametric Mapping. A clinical validation. Neuroimage 1999;9:63-80

[21] Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, Sato M, et al. Tc-99m HMPAO SPECT in the evaluation of Alzheimer’s disease: correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psychiatry 1999;66: 228-232
- Signorini M, Paulesu E, Friston K, Perani D, Lucignani G, Colleluori A, Striano G, et al. Rapid assessment of [18F]FDGPET brain scans in individual patients with Statistical Parametric Mapping. A clinical validation. Neuroimage 1999;9:63-80

[22] Buxton R.B. Introduction to Functional Magnetic Resonance Imaging : Principles and Techniques. Cambridge University Press 2001
- Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol. 2004;66:735-69

[23] Karbe H, Kertesz A, et al. Quantification of functional deficit in Alzheimer’s disease using a computer assisted mapping program for 99mTc-HMPAO SPECT. Neuroradiology 1994;36:1

[24] Messa C, Perani D, et al. High resolution Technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET, Journal of Nuclear Medicine 1994;35:210

[25] Miller BL, Cummings JL, Villanueva-Meyer J, Boone K, Mehringer CR, Lesser IM et al. Frontal lobe degeneration: clinical, neuropsychological and SPECT characteristics. Neurology 1991; 41: 1374-82

[26] Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, Soininen H, Wahlund LO, Waldemar G, Salmon E. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry. 2003;74:1371-81

[27] Herholz K. PET studies in dementia. Ann Nucl Med. 2 003 Apr;17(2):79-89

[28] Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement Geriatr CognDisord 1999;10:494-504

[29] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991;82:239
- Perani D, Bressi S, et al. Evidence of multiple memory systems in the human brain: a (18F)FDG PET metabolic study. Brain 1993;116:903

[30] Alavi A, Newberg AB, et al. Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. Journal of Nuclear Medicine 1993;34:1681

[31] Ibanez V, Pietrini P, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1998;50:1585.49

[32] Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement Geriatr CognDisord 1999;10:494-504

[33] K. Herholz , E. Salmon , D. Perani , J.-C. Baron , V. Holthoff , L. Frölich , P.Schönknecht , K. Ito, R. Mielke , E. Kalbe , G. Zündorf, X. Delbeuck , O.Pelati , D. Anchisi , F. Fazio , N. Kerrouche , C. Calautti , B. Beuthien-Baumann, C. Menzel , J. Schröder , T.Kato , Y. Arahata , M. Henze , W.-D. Heiss Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET. NeuroImage, 2002, 17: 302-316

[34] Kennedy A, Kennedy AN, Newman SK, Rossor MN, Frackowiack RSJ, Cunningham VJ, Roques P, Stevens J, Neary D, Bruton CJ, Warrington EK, Rossor MN. Chromosome 14 linked familial Alzheimer’s disease. A clinico-pathological study of a single pedigree. Brain 1995;118:185-205
- Small GW, Mazziotta JC, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942

[35] Binetti, Signorini, Squitti, et al. Atypical Dementia Associated with a Novel Presenilin-2 Mutation. Ann Neurol 2003;54:832–836

[36] Perani D, Grassi F, Sorbi S, Nacmias B, Piacentini S, Piersanti P, Provinciali L, Amaducci L, Fazio F. PET study in subjects from two Italian FAD families with APP717 Val to Ileu mutation. European Journal of Neurology 1997;4:214-220

[37] Berent S, Giordani B, Foster N, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer’s disease. Journal of Psychiatric Research 1999;33:7

[38] Petersen RC, Doody R, Kurz A, et al. Current concepts in Mild Cognitive Impairment. Arch Neurol 2001;58:1985-92

[39] Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 2001;12(6):379-86)
- Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment. Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003; 60:1374-7
- Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54:343-51

[40] Pullicino P, Benedict RHB, et al. Neuroimaging criteria for vascular dementia. Archives of Neurology 1996;723

[41] Sultzer DL, Mahler ME, et al. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. Archives of Neurology 1995;52:773

[42] M Franceschi, D Anchisi, O Pelati, M Zuffi, M Matarrese, RM Moresco, F Fazio, and D Perani. Cerebral glucose metabolism and 5-HT2A receptor distribution in the frontal variant of Frontotemporal Lobe Degeneration. Annals of Neurology, 2004, 56, in press

[43] Cappa SF, Perani D, et al. Varieties of progressive non-fluent aphasia. In: Growdon JH, Nitsch RM, Corkin S, Wurtman RJ (eds). Neurobiology of Alzheimer’s Disease. New York, The New York Academy of Sciences 1995

[44] Duara R, Barker W, Luis CA. Frontotemporal dementia and Alzheimer’s disease: differential diagnosis. Dement Geriatr Cogn Disord 1999;10:37-42
- Salmon E, Garraux G, Delbeuck X, Collette F, Kalbe E, Zuendorf G et al. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage 2003; 20: 435-40

[45] Lund and Manchester Group. Clinical and neuropathological criteria for frontotemporal dementia, Journal of Neurology Neurosurgery and Psychiatry 1994;57:416

[46] Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, Soininen H, Wahlund LO, Waldemar G, Salmon E. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry. 2003;74:1371-81

[47] Posner MI, Raichle ME. Images of mind. New York, Scientific American Library 1994

[48] Grady CL, McIntosh AR, et al. Age-related reductions in human recognition memory due to impaired encoding. Science 1995;269:218

[49] Becker JT, Mintun MA, et al. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer’s disease. Neurology 1996;46:692
- Cabeza R, Anderson ND, Houle S, Mangels JA, Nyberg L. Age-related differences in neural activity during item and temporal-order memory retrieval: a positron emission tomography study. Journal of Cognitive Neuroscience 2000;12:197-206

[50] Iacoboni M, Baron JC, et al. Emission tomography contribution to clinical neurology (Review). Clinical Neurophysiology 1999;110:2

[51] Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia. 2004;42(7):980-9
- Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ, Smith GE, Tangalos EG, Jack CR Jr. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003 Aug 26;61(4):500-6

[52] Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, Logan J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143-147
- Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, Mathur A, Saffer J. Effects of age on dopamine transporters in healthy humans. Nuclear Medicine 1999;40:1812-1817

[53] Meltzer CC, Smith G, Price JC, Reynolds CF 3rd, Mathis CA, Greer P, Lopresti B, et al. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res. 1998;813:167-171

[54] Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease.Ann Neurol 1996;40:399-410
- Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA., et al. In vivo mapping of cerebral acetylcholinesterase activity in ageing and Alzheimer’s disease. Neurology 1999;10:691-699

[55] Iyo M, Namba H, Fukushi K, Shinotoh H, Nagattsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’sdisease. Lancet 1997;349:1805-1809
- Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s diseaseAnn Neurol 1996;40:399-410

[56] Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, Kalbe E, Heiss WD. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage. 2004 Jan;21(1):136-43

[57] Walker Z, Costa DC, Ince P, McKeith IG, Katona CL. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 1999;354:646-647

[58] Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. In-vivo measurement of activated microglia in dementia. Lancet 2001;11;358(9280):461-467